Pomerantz LLP announces the reopening of the Lead Plaintiff appointment process in a pending securities class action lawsuit on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”)(NASDAQ: SPPI). Investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg
The class action concerns whetherSpectrum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You haveuntil September 24, 2025to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Spectrum securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
Spectrum is a biopharmaceutical company focused on oncology treatments. The class action lawsuitallegesthat Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Danielle Peyton Pomerantz LLPdpeyton@pomlaw.com 646-581-9980 ext. 7980
https://c212.net/c/img/favicon.png?sn=DC47890&sd=2025-08-11
View original content to download multimedia:https://www.prnewswire.com/news-releases/nvestor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-spectrum-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadline—sppi-302525788.html
SOURCE Pomerantz LLP
https://rt.newswire.ca/rt.gif?NewsItemId=DC47890&Transmission_Id=202508111000PR_NEWS_USPR_____DC47890&DateId=20250811